Fundraising Fox
🦊/Companies
Sign in

Armis Biopharma

Fort Collins, US · Delaware corporation

Find your way into Armis Biopharma

694 people in our graph share verified history with the Armis Biopharma team — schools, employers, funds. One of them is your warm intro.

Sydney Sloanunlockedknows Michael Handley · together at University of Southern California (overlapped)
×3knows the team · via Pepperdine Graziadio Business School
×5knows the team · via Amgen
×2knows the team · via Wharton Executive Education
knows the team · via Iowa State University

Armis Biopharma develops targeted antimicrobial therapies designed to treat and prevent localized, drug-resistant infections by delivering medications locally to increase efficacy and reduce systemic toxicity.

BiotechHealthtechMedical Devices

Founders & leadership

SCSteve Coder
Steve CoderinChief Financial OfficerSteve Coder is an executive with over 20 years of experience in general management, manufacturing, finance, and operations, with background in M&A, product development, and strategic business direction. He serves as Executive Officer and Director at Armis Biopharma, which develops targeted antimicrobial therapies to treat drug-resistant infections.
MVMichael Voss
Michael VossinChief Executive OfficerHe has held leadership roles in research and development, sales, marketing, and operations across pre-revenue startups and established medical device and healthcare companies, and holds a patent related to pleural effusion treatment technology.
RK
Robert KaliExecutive
DT
Dennis TemplarExecutive
MHMichael Handley
Michael HandleyinChief Executive Officer & Director2012–2018Michael Handley has over 25 years of experience in life sciences and holds leadership positions including CEO of Valion Bio and President of Velocity Bioworks, with background spanning multiple therapeutic areas and business functions.

Board

AR
Alan RuudBoard director
TZ
Theodore ZiemannBoard director
WN
William Nelson, MD, Ph.D.Board director
ML
Michael LitwackBoard director
AS
Alan Smith, Ph.D.Board director
CR
Christopher RuddBoard director
WN
William Nelson, VBoard director

Reported raises · per SEC filings

Form D private placements

$21.2M disclosed across 8 rounds · 2014–2025

▶$1MraisedJul 2025 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Theodore ZiemannDirector
  • Alan RuudDirector
  • Steve CoderExecutive Officer, Director
  • Michael VossExecutive Officer, Director
  • William Nelson, MD, Ph.D.Director
  • Michael LitwackDirector
  • Alan Smith, Ph.D.Director
  • Christopher RuddDirector
Offering amount
$3M
Amount sold
$1M
Proceeds to insiders
$150K
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.3MraisedSep 2022 · 14 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ted ZiemannExecutive Officer, Director
  • William Nelson, MD. Ph.D.Director
  • Ed Neas, Ph.D.Director
  • Michael LitwackDirector
  • Steve CoderExecutive Officer, Director
  • Christopher RuudExecutive Officer, Director
  • Alan Smith, Ph.D.Director
  • Alan RuudDirector
Offering amount
$10M
Amount sold
$7.3M
First sale
May 2020
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedSep 2018 · 19 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen CoderDirector
  • William NelsonDirector
  • Michael LitwackDirector
  • Robert KaliExecutive Officer
  • Ted ZiemannExecutive Officer, Director
  • Alan SmithDirector
  • Ed NeasDirector
  • Dennis TemplarExecutive Officer, Director
  • Alan RuudDirector
Offering amount
$10M
Amount sold
$1.8M
Sales commissions
$490.1K
Placement agents
Arete Wealth Management, LLC
First sale
Jun 2018
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MraisedNov 2017 · 7 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ed NeasExecutive Officer, Director
  • William NelsonDirector
  • Michael HandleyExecutive Officer, Director
  • Dennis TemplarExecutive Officer, Director
  • Robert KaliExecutive Officer
  • Stephen CoderDirector
  • Alan RuudDirector
  • Alan SmithDirector
  • Ted ZiemannExecutive Officer, Director
  • Michael LitwackDirector
Offering amount
$14M
Amount sold
$2.7M
Sales commissions
$840K
Placement agents
TORREYA CAPITAL, CG CAPITAL MARKETS LLC, PRECISION SECURITIES, LLC
First sale
Feb 2017
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedNov 2017 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael LitwackDirector
  • Stephen CoderDirector
  • William NelsonDirector
  • Alan RuudDirector
  • Michael HandleyExecutive Officer, Director
  • Robert KaliExecutive Officer
  • Dennis TemplarExecutive Officer, Director
  • Alan SmithDirector
  • Ed NeasExecutive Officer, Director
  • Ted ZiemannExecutive Officer, Director
Offering amount
$30M
Amount sold
$125K
Sales commissions
$1.8M
Placement agents
APPLIED CAPITAL, LLC, PRECISION SECURITIES, LLC
First sale
Oct 2017
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.3MraisedJun 2016 · 16 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William Nelson, VDirector
  • Roy Carver, Jr.Director
  • Stephen CoderDirector
  • Alan SmithDirector
  • Ted ZiemannExecutive Officer, Director
  • Loretta MealyDirector
  • Dennis TemplarExecutive Officer, Director
  • Alan RuudDirector
  • Ed NeasDirector
  • Michael HandleyExecutive Officer, Director
  • Michael LitwackDirector
  • Robert KaliExecutive Officer
Offering amount
$5.8M
Amount sold
$3.3M
Sales commissions
$203.6K
Placement agents
DONENFELD, ALAN PAUL
First sale
Jan 2016
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedFeb 2016 · 19 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert KaliExecutive Officer
  • Michael LitwackDirector
  • William Nelson, VDirector
  • Dennis TemplarExecutive Officer, Director
  • Doug CoderDirector
  • Alan SmithDirector
  • Ted ZiemannDirector
  • Ed NeasDirector
  • Roy, Jr. CarverDirector
  • Michael HandleyExecutive Officer, Director
  • Loretta MealyDirector
Offering amount
$1.7M
Amount sold
$1.7M
First sale
Mar 2015
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedApr 2014 · 20 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy, Jr. CarverDirector
  • Michael HandleyExecutive Officer
  • Doug CoderDirector
  • Ted ZiemannDirector
  • Michael LitwackDirector
  • Dennis TemplarExecutive Officer, Director
  • Robert KaliExecutive Officer
  • Ed NeasDirector
  • Alan SmithDirector
  • Cathy SohnDirector
  • Loretta MealyDirector
Offering amount
$3.2M
Amount sold
$3.2M
First sale
Feb 2014
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Alumis7 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Amicus Therapeutics5 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
IRIS MEDICINE5 shared keywordsIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.

Companies competing with Armis Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$1.4M
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$694.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Armis Biopharma do?
Armis Biopharma develops targeted antimicrobial therapies designed to treat and prevent localized, drug-resistant infections by delivering medications locally to increase efficacy and reduce systemic toxicity.
How much funding has Armis Biopharma raised?
Armis Biopharma has disclosed $21.2M raised across 8 rounds.
Where is Armis Biopharma headquartered?
Armis Biopharma is headquartered in Fort Collins, US.